Histone Deacetylases and Mood Disorders: Epigenetic Programming in Gene-Environment Interactions

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 699-704

  Machado Vieira, Rodrigo ^a,b   Ibrahim, Lobna ^a   Zarate Jr , Carlos A ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Bipolar disorder; Depression; Epigenetics; Histones; Pathophysiology; Treatment; Valproate

Indexed keywords

4 PHENYLBUTYRIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; BUTYRIC ACID; ENTINOSTAT; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; PANOBINOSTAT; ROMIDEPSIN; TACEDINALINE; TRAPOXIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACETYLATION; BEHAVIOR; BIPOLAR DISORDER; CHROMATIN; COGNITION; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; ENZYME POLYMORPHISM; EPIGENETICS; GENE EXPRESSION; GENOTYPE ENVIRONMENT INTERACTION; HISTONE MODIFICATION; HUMAN; MAJOR DEPRESSION; MOOD DISORDER; NONHUMAN; REVIEW;

ACETYLATION; ANIMALS; ANTIMANIC AGENTS; EPIGENESIS, GENETIC; GENE-ENVIRONMENT INTERACTION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MOOD DISORDERS; VALPROIC ACID;

EID: 82355175410     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00203.x     Document Type: Review

References (77)

1. Judd LL, Schettler PJ, Akiskal HS, Coryell W, Leon AC, Maser JD, Solomon DA. Residual symptom recovery from major affective episodes in bipolar disorders and rapid episode relapse/recurrence. Arch Gen Psychiatry 2008;65:386-394.
2. Berk M, Hallam K, Lucas N, et al. Early intervention in bipolar disorder: Opportunities and pitfalls. Med J Aust 2007;187(Suppl 7):S11-S14.
3. McGorry PD, Nelson B, Amminger GP, et al. Intervention in individuals at ultra high risk for psychosis: A review and future directions. J Clin Psychiatry 2009;70:1206-1212.
4. Salvadore G, Drevets WC, Henter ID, Zarate CA, Manji HK. Early intervention in bipolar disorder, part I: Clinical and imaging findings. Early Interv Psychiatry 2008;2:122-135.
5. Curtis C. Sexual abuse and subsequent suicidal behaviour. Exacerbating factors and implications for recovery. J Child Sex Abuse 2006;15:1-21.
6. Otto MW, Perlman CA, Wernicke R, Reese HE, Bauer MS, Pollack MH. Posttraumatic stress disorder in patients with bipolar disorder: A review of prevalence, correlates, and treatment strategies. Bipolar Disord 2004;6:470-479.
7. Rutten BP, Mill J. Epigenetic mediation of environmental influences in major psychotic disorders. Schizophr Bull 2009;35:1045-1056.
8. Kato T, Iwamoto K, Kakiuchi C, Kuratomi G, Okazaki Y. Genetic or epigenetic difference causing discordance between monozygotic twins as a clue to molecular basis of mental disorders. Mol Psychiatry 2005;10:622-630.
9. Santini V, Gozzini A, Ferrari G. Histone deacetylase inhibitors: Molecular and biological activity as a premise to clinical application. Curr Drug Metab 2007;8:383-393.
10. Allis CD, Jenuwein T, Reinberg D. Overview and concepts. Allis CD, Jenuwein T, Reinberg D, et al., editors. Epigenetics. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2007;23-61.
11. Monneret C. Histone deacetylase inhibitors. Eur J Med Chem 2005;40:1-13.
12. Wolffe AP. Nucleosome positioning and modification: Chromatin structures that potentiate transcription. Trends Biochem Sci 1994;19:240-244.
13. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007;76:75-100.
14. Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell 2004;117:721-733.
15. Peterson CL, Laniel MA. Histones and histone modifications. Curr Biol 2004;14:R546-R551.
16. Weaver IC, Cervoni N, Champagne FA, et al. Epigenetic programming by maternal behavior. Nat Neurosci 2004;7:847-854.
17. McGowan PO, Sasaki A, D'Alessio AC, et al. Epigenetic regulation of the glucocorticoid receptor in human brain associates with childhood abuse. Nat Neurosci 2009;12:342-348.
18. Van Lint C, Emiliani S, Verdin E. The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr 1996;5:245-253.
19. Carey N, La Thangue NB. Histone deacetylase inhibitors: Gathering pace. Curr Opin Pharmacol 2006;6:369-375.
20. Kazantsev AG, Thompson LM. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov 2008;7:854-868.
21. Covington HE 3rd, Maze I, LaPlant QC, et al. Antidepressant actions of histone deacetylase inhibitors. J Neurosci 2009;29:11451-11460.
22. Gavin DP, Kartan S, Chase K, Jayaraman S, Sharma SP. Histone deacetylase inhibitors and candidate gene expression: An in vivo and in vitro approach to studying chromatin remodeling in a clinical population. J Psychiatr Res 2009;43:870-876.
23. Hobara T, Uchida S, Otsuki K, et al. Altered gene expression of histone deacetylases in mood disorder patients. J Psychiatr Res 2010;44:263-270.
24. Otsuki K, Uchida S, Wakabayashi Y, Matusbara T, Hobara T, Funato H, Watanabe Y. Aberrant REST-mediated transcriptional regulation in major depressive disorder. J Psychiatr Res 2010;44:378-384.
25. Ng HH, Bird A. Histone deacetylases: Silencers for hire. Trends Biochem Sci 2000;25:121-126.
26. Simonini MV, Camargo LM, Dong E, Maloku E, Veldic M, Costa E, Guidotti A. The benzamide MS-275 is a potent, long-lasting brain region-selective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006;103:1587-1592.
27. Kundakovic M, Chen Y, Guidotti A, Grayson DR. The Reelin and GAD67 promotors are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol 2009;75:342-354.
28. Sharma R, Ottenhof T, Rzeczkowska PA, Niles NP. Epigenetic targets for melatonInduction of histone H3 hyperacetylation and gene expression in C17.2 neural stem cells. J Pineal Res 2008;45:277-284.
29. Guidotti A, Auta J, Davis JM, et al. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: A postmortem brain study. Arch Gen Psychiatry 2000;57:1061-1069.
30. Benes FM, Berretta S. GABAergic interneurons: Implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001;25:1-27.
31. Dong E, Guidotti A, Grayson DR, Costa E. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci USA 2007;104:4676-4681.
32. Kundakovic M, Chen Y, Costa E, Grayson DR. DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol 2007;71:644-653.
33. Lu Q, Hutchins AE, Doyle CM, Lundblad JR, Kwok RP. Acetylation of cAMP-responsive element-binding protein (CREB) by CREB-binding protein enhances CREB-dependent transcription. J Biol Chem 2003;278:15727-15734.
34. Mamdani F, Alda M, Grof P, Young LT, Rouleau G, Turecki G. Lithium response and genetic variation in the CREB family of genes. Am J Med Genet B Neuropsychiatr Genet 2008;147B:500-504.
35. Manji HK, Quiroz JA, Payne JL, Singh J, Lopes BP, Viegas JS, Zarate CA. The underlying neurobiology of bipolar disorder. World Psychiatry 2003;2:136-146.
36. Wood MA, Hawk JD, Abel T. Combinatorial chromatin modifications and memory storage: A code for memory? Learn Mem 2006;13:241-244.
37. Alarcon JM, Malleret G, Touzani K, Vronskaya S, Ishii S, Kandel ER, Barco A. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: A model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. Neuron 2004;42:947-959.
38. Guan Z, Giustetto M, Lomvardas S, et al. Integration of long-term-memory-related synaptic plasticity involves bidirectional regulation of gene expression and chromatin structure. Cell 2002;111:483-493.
39. Levenson JM, O'Riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 2004;279:40545-40559.
40. Vecsey CG, Hawk JD, Lattal KM, et al. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J Neurosci 2007;27:6128-6140.
41. Yeh SH, Lin CH, Gean PW. Acetylation of nuclear factor-kappaB in rat amygdala improves long-term but not short-term retention of fear memory. Mol Pharmacol 2004;65:1286-1292.
42. Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: Convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord 2009;11(Suppl 2):92-109.
43. Sleiman SF, Basso M, Mahishi L, Kozikowski AP, Donohoe ME, Langley B, Ratan RR. Putting the 'HAT' back on survival signalling: The promises and challenges of HDAC inhibition in the treatment of neurological conditions. Expert Opin Investig Drugs 2009;18:573-584.
44. Langley B, Gensert JM, Beal MF, Ratan RR. Remodeling chromatin and stress resistance in the central nervous system: Histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 2005;4:41-50.
45. Leverich GS, Altshuler LL, Frye MA, et al. Factors associated with suicide attempts in 648 patients with bipolar disorder in the Stanley Foundation Bipolar Network. J Clin Psychiatry 2003;64:506-515.
46. Schroeder FA, Lin CL, Crusio WE, Akbarian S. Antidepressant-like effects of the histone deacetylase inhibitor, sodium butyrate, in the mouse. Biol Psychiatry 2007;62:55-64.
47. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci 2006;9:519-525.
48. Ryu H, Lee J, Olofsson BA, et al. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci USA 2003;100:4281-4286.
49. Langley B, D'Annibale MA, Suh K, et al. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J Neurosci 2008;28:163-176.
50. Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN. Oxidative stress markers in bipolar disorder: A meta-analysis. J Affect Disord 2008;111:135-144.
51. Machado-Vieira R, Andreazza AC, Viale CI, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects. Neurosci Lett 2007;421:33-36.
52. Leng Y, Liang MH, Ren M, Marinova Z, Leeds P, Chuang DM. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: Roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008;28:2576-2588.
53. Kwon B, Houpt TA. Phospho-acetylation of histone H3 in the amygdala after acute lithium chloride. Brain Res 2010;1333:36-47.
54. Chen PS, Peng GS, Li G, et al. Valproate protects dopaminergic neurons in midbrain neuron/glia cultures by stimulating the release of neurotrophic factors from astrocytes. Mol Psychiatry 2006;11:1116-1125.
55. Wu X, Chen PS, Dallas S, et al. Histone deacetylase inhibitors up-regulate astrocyte GDNF and BDNF gene transcription and protect dopaminergic neurons. Int J Neuropsychopharmacol 2008;11:1123-1134.
56. Bredy TW, Wu H, Crego C, Zellhoefer J, Sun YE, Barad M. Histone modifications around individual BDNF gene promoters in prefrontal cortex are associated with extinction of conditioned fear. Learn Mem 2007;14:268-276.
57. Chwang WB, O'Riordan KJ, Levenson JM, Sweatt JD. ERK/MAPK regulates hippocampal histone phosphorylation following contextual fear conditioning. Learn Mem 2006;13:322-328.
58. Yuan P, Zhou R, Wang Y, et al. Altered levels of extracellular signal-regulated kinase signaling proteins in postmortem frontal cortex of individuals with mood disorders and schizophrenia. J Affect Disord 2010;124:164-169.
59. Lattal KM, Barrett RM, Wood MA. Systemic or intrahippocampal delivery of histone deacetylase inhibitors facilitates fear extinction. Behav Neurosci 2007;121:1125-1131.
60. Gottlicher M, Minucci S, Zhu P, et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 2001;20:6969-6978.
61. Tremolizzo L, Rodriguez-Menendez V, Sala G, Di Francesco JC, Ferrarese C. Valproate and HDAC inhibition: A new epigenetic strategy to mitigate phenotypic severity in ALS? Amyotroph Lateral Scler Other Motor Neuron Disord 2005;6:185-186.
62. Chen PS, Wang CC, Bortner CD, et al. Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience 2007;149:203-212.
63. Gurvich N, Berman MG, Wittner BS, Gentleman RC, Klein PS, Green JB. Association of valproate-induced teratogenesis with histone deacetylase inhibition in vivo. FASEB J 2005;19:1166-1168.
64. Leng Y, Chuang DM. Endogenous alpha-synuclein is induced by valproic acid through histone deacetylase inhibition and participates in neuroprotection against glutamate-induced excitotoxicity. J Neurosci 2006;26:7502-7512.
65. Chuang DM. The antiapoptotic actions of mood stabilizers: Molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005;1053:195-204.
66. Sharma RP, Rosen C, Kartan S, Guidotti A, Costa E, Grayson DR, Chase K. Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: Preliminary results from a clinical population. Schizophr Res 2006;88:227-231.
67. Nakajima T, Fukamizu A, Takahashi J, Gage FH, Fisher T, Blenis J, Montminy MR. The signal-dependent coactivator CBP is a nuclear target for pp90RSK. Cell 1996;86:465-474.
68. Steffan JS, Bodai L, Pallos J, et al. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila. Nature 2001;413:739-743.
69. Drummond DC, Noble CO, Kirpotin DB, Guo Z, Scott GK, Benz CC. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu Rev Pharmacol Toxicol 2005;45:495-528.
70. Meisel A, Harms C, Yildirim F, et al. Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J Neurochem 2006;98:1019-1031.
71. Ferrante RJ, Kubilus JK, Lee J, et al. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23:9418-9427.
72. Hockly E, Richon VM, Woodman B, et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease. Proc Natl Acad Sci USA 2003;100:2041-2046.
73. Thomas EA, Coppola G, Desplats PA, et al. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc Natl Acad Sci USA 2008;105:15564-15569.
74. Petri S, Kiaei M, Kipiani K, Chen J, Calingasan NY, Crow JP, Beal MF. Additive neuroprotective effects of a histone deacetylase inhibitor and a catalytic antioxidant in a transgenic mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 2006;22:40-49.
75. Greene E, Mahishi L, Entezam A, Kumari D, Usdin K. Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia. Nucleic Acids Res 2007;35:3383-3390.
76. Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM. Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia. Nat Chem Biol 2006;2:551-558.
77. Rai M, Soragni E, Jenssen K, et al. HDAC inhibitors correct frataxin deficiency in a Friedreich ataxia mouse model. PLoS One 2008;3:e1958.